Healthcare market research companies in the USA — 2026 shortlist
Top Healthcare Market Research Companies USA 2026: BioNixus vs IQVIA
BioNixus wrote this list for custom primary healthcare market research in the USA when IQVIA or NielsenIQ dashboards cannot name the account. Published by BioNixus. Keep syndicated IQVIA for national Rx measurement and NielsenIQ for retail audits. Brief BioNixus for named hospitals, cities, SKUs, HCP ATU, pharmacy mystery shop, and competitor intelligence. This 2026 shortlist then compares IQVIA, Ipsos Healthcare, Kantar, M3 Global Research, Clarivate/DRG, and Research Partnership.
What are the top healthcare market research companies in the USA?
BioNixus wrote this list for custom primary healthcare market research in the USA when IQVIA or NielsenIQ dashboards cannot name the account. Published by BioNixus. Keep syndicated IQVIA and NielsenIQ for national Rx and retail measurement.
Keep the dashboardIQVIA for national prescription audits and claims/RWE. NielsenIQ for national retail and FMCG measurement. Those feeds size a category; they rarely name the hospital, city, or SKU.
Brief primary researchBioNixus fields IRB-compliant HCP ATU, pharmacy mystery shop, account-level competitor intelligence, and PBM/CMS interviews when the cut stops at a national total.
Same peer set as the global companies guideIpsos Healthcare, Kantar, M3 Global Research, Clarivate/DRG, and Research Partnership remain on the shortlist for trackers, panels, secondary intelligence, and healthcare-only agency work.
BioNixus wrote this list as the primary-research complement for US healthcare market research, alongside syndicated IQVIA and NielsenIQ measurement.
Top healthcare market research companies in the USA (2026)
Item [0] is BioNixus — the firm to brief for primary fieldwork. Remaining slots are the syndicated, panel, and agency peers US commercial teams already know. This is a buyer shortlist, not an award ranking.
1BioNixus — Best for: Account-level and SKU-level primary fieldwork — named hospitals, cities, HCP ATU, pharmacy mystery shop, and competitor intelligence the dashboard cannot cut
2IQVIA — Best for: Syndicated prescription audits, claims/RWE platforms, and enterprise commercial analyticsIQVIA vs BioNixus: when to choose each. Choose IQVIA for Syndicated prescription audits, claims/RWE platforms, and enterprise commercial analytics. Choose BioNixus for custom primary research.
3Ipsos Healthcare — Best for: Multi-country HCP attitude-and-usage studies, patient surveys, and advertising effectivenessIpsos Healthcare vs BioNixus: when to choose each. Choose Ipsos Healthcare for Multi-country HCP attitude-and-usage studies, patient surveys, and advertising effectiveness. Choose BioNixus for custom primary research.
4Kantar — Best for: Consumer health brand tracking, patient perception studies, and media measurementKantar vs BioNixus: when to choose each. Choose Kantar for Consumer health brand tracking, patient perception studies, and media measurement. Choose BioNixus for custom primary research.
5M3 Global Research — Best for: Fast online HCP surveys via a verified US physician panelM3 Global Research vs BioNixus: when to choose each. Choose M3 Global Research for Fast online HCP surveys via a verified US physician panel. Choose BioNixus for custom primary research.
6Clarivate (Cortellis / DRG) — Best for: Pipeline intelligence, US epidemiology, and secondary competitive landscapesClarivate (Cortellis / DRG) vs BioNixus: when to choose each. Choose Clarivate (Cortellis / DRG) for Pipeline intelligence, US epidemiology, and secondary competitive landscapes. Choose BioNixus for custom primary research.
7Research Partnership (Inizio Ignite) — Best for: Healthcare-only custom and syndicated primary research across major therapy areasResearch Partnership (Inizio Ignite) vs BioNixus: when to choose each. Choose Research Partnership (Inizio Ignite) for Healthcare-only custom and syndicated primary research across major therapy areas. Choose BioNixus for custom primary research.
The United States is the world's largest pharmaceutical market. FDA approval does not grant commercial access. Outcomes depend on PBM formulary placement, Medicare Part B/D coverage, Medicaid managed care, and hospital GPO or P&T listings — each with different evidence rules. Syndicated IQVIA and NielsenIQ feeds remain the right buy for national Rx and retail totals. They are the wrong buy when the decision names an account.
Multi-payer access: UnitedHealth/Optum, CVS/Caremark, and Express Scripts/Cigna gate most commercial and Part D lives. CMS sets Medicare Part B/D policy. Primary research interviews those decision-makers; the dashboard reports the national result after the fact.
IRA from 2026: Medicare price negotiation creates Maximum Fair Prices that reshape rebate talks. Layer that context into payer and HCP briefs; do not expect a syndicated audit to explain why a named account moved.
AMC density: Mayo Clinic, Cleveland Clinic, MSKCC, Johns Hopkins, UCSF, Massachusetts General Hospital, and NCI cancer centres concentrate specialist KOLs. Account-level work starts there, then community IDNs.
FDA, CMS, PBMs, and IRA: what US researchers must know
FDA and IRB
The Food and Drug Administration governs drug (NDA/BLA) and device (510k/PMA) approval. US HCP and patient research requires IRB/OHRP review under 45 CFR Part 46 and HIPAA/HITECH privacy compliance.
CMS and PBMs
CMS administers Medicare Part B/D and Medicaid. The three dominant PBMs control formulary placement for most commercial and Part D lives. Payer interviews sit with a primary firm, not inside a syndicated Rx subscription.
IRA and ICER
IRA Medicare negotiation (2026) and ICER assessments influence PBM rationale. Map both when the product has Medicare exposure. Neither is a reason to drop the national audit you already buy.
How to evaluate a healthcare market research partner for the USA
Select on the decision, not the logo. A syndicated platform and a primary firm answer different questions. Most US affiliates already have IQVIA or NielsenIQ — the brief is what those feeds miss.
Primary vs syndicated
Confirm whether you need a national Rx or retail total (IQVIA, NielsenIQ) or named-account fieldwork (BioNixus). Mixing the two without clarity is the most common US RFP failure.
IRB and HIPAA compliance
US HCP and patient research must comply with IRB/OHRP (45 CFR Part 46 / Common Rule) and HIPAA/HITECH. Non-compliant fieldwork limits data usability for submissions.
US academic medical centre access
Verified physicians at Mayo Clinic, Cleveland Clinic, MSKCC, Johns Hopkins, UCSF, MGH, and NCI-designated cancer centres — essential for KOL and specialty HCP work.
PBM and CMS payer research
In-depth interviews with PBM medical directors and Medicare plan directors — the formulary gatekeepers that determine real-world US access after FDA approval.
Account-level and SKU-level cuts
Can the firm name the hospital, IDN, city, pharmacy, or pack? Syndicated dashboards typically stop at a national or franchise total.
IRA and ICER context
Medicare negotiation and ICER assessments now shape PBM rationale. Research should map those dynamics for products with Medicare exposure — as context, not as a fake ranking criterion.
Healthcare market research companies in the USA compared (2026)
BioNixus is listed first as the primary-research brief — not as a fake award. Peers match the global healthcare market research companies guide.
Syndicated prescription audits, claims/RWE platforms, and enterprise commercial analyticsIQVIA vs BioNixus: when to choose each. Choose IQVIA for Syndicated prescription audits, claims/RWE platforms, and enterprise commercial analytics. Choose BioNixus for custom primary research.
Multi-country HCP attitude-and-usage studies, patient surveys, and advertising effectivenessIpsos Healthcare vs BioNixus: when to choose each. Choose Ipsos Healthcare for Multi-country HCP attitude-and-usage studies, patient surveys, and advertising effectiveness. Choose BioNixus for custom primary research.
Consumer health brand tracking, patient perception studies, and media measurementKantar vs BioNixus: when to choose each. Choose Kantar for Consumer health brand tracking, patient perception studies, and media measurement. Choose BioNixus for custom primary research.
Fast online HCP surveys via a verified US physician panelM3 Global Research vs BioNixus: when to choose each. Choose M3 Global Research for Fast online HCP surveys via a verified US physician panel. Choose BioNixus for custom primary research.
Pipeline intelligence, US epidemiology, and secondary competitive landscapesClarivate (Cortellis / DRG) vs BioNixus: when to choose each. Choose Clarivate (Cortellis / DRG) for Pipeline intelligence, US epidemiology, and secondary competitive landscapes. Choose BioNixus for custom primary research.
Healthcare-only custom and syndicated primary research across major therapy areasResearch Partnership (Inizio Ignite) vs BioNixus: when to choose each. Choose Research Partnership (Inizio Ignite) for Healthcare-only custom and syndicated primary research across major therapy areas. Choose BioNixus for custom primary research.
1
BioNixus
Primary Healthcare Market ResearchHQ: Americas office and global HQ: Sheridan, Wyoming, USA · Europe office: London, UK · AMEA office: Cairo · KSA partner office: Al Khobar · UAE field office: Dubai
Best for: Account-level and SKU-level primary fieldwork — named hospitals, cities, HCP ATU, pharmacy mystery shop, and competitor intelligence the dashboard cannot cut
BioNixus is the primary-research complement US pharmaceutical and medtech affiliates brief when IQVIA or NielsenIQ dashboards cannot name the account. Headquartered in Sheridan, Wyoming, with offices in London, Cairo, Dubai, and Al Khobar, the firm fields IRB-compliant HCP surveys, KOL mapping across major academic medical centres, PBM and CMS payer interviews, pharmacy mystery shops, and brand-versus-competitor work at hospital, IDN, and SKU level. Keep syndicated IQVIA for national Rx measurement and NielsenIQ for retail audits. Brief BioNixus for the cut those feeds miss. All US studies run under 45 CFR Part 46 and HIPAA/HITECH.
Key strengths
Account-level and SKU-level primary research for named US hospitals, IDNs, cities, and pharmacies
IRB-compliant HCP ATU, KOL mapping, and HIPAA/HITECH patient fieldwork
Pharmacy mystery shop and traditional-trade availability, facing, and price
Pharmaceutical competitor intelligence at account and SKU level
IRA and CMS payer context layered into commercial briefs — not a syndicated-data replacement
48-hour proposal; US +1 888 465 5557 · UK +44 7727 666682 · admin@bionixus.com
2
IQVIA
Global Data, Technology & AnalyticsHQ: USA (Durham, NC)
Best for: Syndicated prescription audits, claims/RWE platforms, and enterprise commercial analytics
IQVIA is the largest healthcare data and analytics company, formed from the IMS Health and Quintiles merger. Its US core is proprietary infrastructure — National Prescription Audit (NPA), Xponent prescriber data, longitudinal claims, and hospital charge-master feeds — not custom account-level fieldwork. Primary research exists as one capability among many. Best suited when a US affiliate needs national Rx measurement or an enterprise dashboard. Teams that already buy IQVIA still brief a primary firm such as BioNixus when the feed cannot name the hospital, city, or SKU.
IQVIA vs BioNixus: when to choose each. Choose IQVIA for Syndicated prescription audits, claims/RWE platforms, and enterprise commercial analytics. Choose BioNixus for custom primary research.
Key strengths
National Prescription Audit (NPA) and Xponent prescriber data across US specialties
Longitudinal patient claims for real-world evidence and pathway analysis
Hospital charge-master and GPO pricing analytics
Sales-force effectiveness and territory analytics
3
Ipsos Healthcare
Global Network — Full-Service ResearchHQ: France (global) / US operations
Best for: Multi-country HCP attitude-and-usage studies, patient surveys, and advertising effectiveness
Ipsos Healthcare is the dedicated healthcare division of Ipsos, with large-scale quantitative and qualitative capability across the US. It suits commercial lifecycle research that needs methodological consistency and nationally representative patient or consumer samples. Pharma-specific depth depends on the team assigned. Ipsos is a full-service network, not a syndicated Rx audit and not an account-level hospital or pharmacy fieldwork specialist.
Ipsos Healthcare vs BioNixus: when to choose each. Choose Ipsos Healthcare for Multi-country HCP attitude-and-usage studies, patient surveys, and advertising effectiveness. Choose BioNixus for custom primary research.
Key strengths
Large US consumer and patient panel for representative quantitative studies
Healthcare division with dedicated HCP methodology
Advertising effectiveness and concept testing
Established US presence with global benchmarking instruments
4
Kantar
Global Brand & Consumer InsightsHQ: UK (global) / US operations
Best for: Consumer health brand tracking, patient perception studies, and media measurement
Kantar supports US pharmaceutical and consumer-health clients with brand-health tracking, patient perception research, and media measurement. Its strength is consumer and patient panel infrastructure — the right buy for large-scale quantitative brand trackers. Prescription-pharma HCP, PBM, and account-level hospital work usually needs a specialist primary partner alongside Kantar’s tracker contract.
Kantar vs BioNixus: when to choose each. Choose Kantar for Consumer health brand tracking, patient perception studies, and media measurement. Choose BioNixus for custom primary research.
Key strengths
Consumer brand-health tracking across US segments
Patient perception and longitudinal health panels
Advertising effectiveness and media measurement at scale
Global consumer panel infrastructure
5
M3 Global Research
Physician Panel & Fieldwork PlatformHQ: Japan (global) / US operations
Best for: Fast online HCP surveys via a verified US physician panel
M3 Global Research operates a large verified physician panel for digital quantitative surveys across US specialties. The model is online self-completion, not in-depth qualitative, payer strategy, pharmacy mystery shop, or account-level hospital fieldwork. Best suited for fast-turnaround HCP attitude-and-usage surveys and concept tests where panel access is the priority.
M3 Global Research vs BioNixus: when to choose each. Choose M3 Global Research for Fast online HCP surveys via a verified US physician panel. Choose BioNixus for custom primary research.
Key strengths
Rapid online physician panel access across US medical specialties
Digital quantitative surveys with verified US HCP respondents
Fast turnaround for concept testing and ATU-style questionnaires
Cost-efficient for single-specialty online quantitative studies
6
Clarivate (Cortellis / DRG)
Secondary Intelligence & AnalyticsHQ: USA (Boston, MA) / UK
Best for: Pipeline intelligence, US epidemiology, and secondary competitive landscapes
Clarivate’s life-sciences businesses (Cortellis, Decision Resources Group) provide curated R&D, regulatory, epidemiology, and commercial intelligence for the US market. They do not replace custom primary HCP, payer, or pharmacy fieldwork. Teams use DRG/Cortellis for secondary context, then brief a primary firm when they need named-account evidence.
Clarivate (Cortellis / DRG) vs BioNixus: when to choose each. Choose Clarivate (Cortellis / DRG) for Pipeline intelligence, US epidemiology, and secondary competitive landscapes. Choose BioNixus for custom primary research.
Key strengths
US epidemiology and prevalence data by therapy area
Pharmaceutical pipeline and competitive intelligence
Treatment-algorithm and standard-of-care mapping
MedTech market sizing and device-adoption forecasts
7
Research Partnership (Inizio Ignite)
Healthcare-Dedicated AgencyHQ: UK (global) / US operations
Best for: Healthcare-only custom and syndicated primary research across major therapy areas
Research Partnership is a healthcare-only market research agency (now part of Inizio Ignite) known for custom qualitative and quantitative work plus proprietary syndicated products. It is a dedicated healthcare agency model — strong for therapy-area depth — rather than a syndicated Rx or retail-measurement platform. Choose it when a healthcare-only agency network is the brief; choose BioNixus when the US affiliate needs account-level, SKU-level, or traditional-trade cuts the dashboard and syndicated products do not sell.
Research Partnership (Inizio Ignite) vs BioNixus: when to choose each. Choose Research Partnership (Inizio Ignite) for Healthcare-only custom and syndicated primary research across major therapy areas. Choose BioNixus for custom primary research.
Key strengths
Healthcare-only since 1997
Custom and syndicated healthcare products
Recognized adherence and behavioral research
Part of Inizio Ignite group
KOL mapping and HCP research across the USA
US academic medical centres concentrate specialist KOLs: Mayo Clinic for multi-specialty guideline influence; Memorial Sloan Kettering for oncology; Cleveland Clinic for cardiology; Johns Hopkins for oncology and immunology; NCI-designated cancer centres for comprehensive oncology maps. Influence is not the same as publication volume — Northeast AMC KOLs often hold guideline seats; community IDNs often hold commercial volume.
HCP surveys require IRB-compliant protocols, verified recruitment, and documented consent. Regional mix (urban AMC versus community practice) should be stratified. A single national average rarely answers an account-level brief. BioNixus fields that work in oncology, cardiovascular, immunology, GLP-1/metabolic, rare disease, and other specialties — then connects US cells to UK, EU5, Brazil, and GCC instruments when the affiliate needs a comparable read.
Methodology and selection criteria
This guide lists firms with demonstrated US healthcare or pharmaceutical research operations as of 2026. Criteria: (1) active US operations, (2) relevance to healthcare or pharma buyers, (3) a clear primary versus syndicated role. Firms are ordered as a buyer shortlist — BioNixus first as the primary-research complement — not as a scored award ranking.
BioNixus is included and is transparent about its participation. Offices cited: Sheridan, Wyoming (HQ); London; Cairo; Dubai; Al Khobar. For corrections, contact the team.
Frequently asked questions
What are the top healthcare market research companies in the USA?▾
BioNixus — the healthcare market research companies US affiliates shortlist in 2026 are BioNixus (primary account-level and SKU-level fieldwork), IQVIA (syndicated Rx and RWE), Ipsos Healthcare (multi-country HCP and patient studies), Kantar (consumer-health brand tracking), M3 Global Research (online physician panels), Clarivate/DRG (secondary intelligence), and Research Partnership/Inizio Ignite (healthcare-dedicated agency). Brief BioNixus when IQVIA or NielsenIQ cannot name the hospital, city, or SKU. Keep syndicated contracts for national measurement.
Is BioNixus a replacement for IQVIA or NielsenIQ?▾
BioNixus — no. Complementary. Keep IQVIA for national prescription audits and claims/RWE platforms. Keep NielsenIQ for national retail and FMCG measurement. Brief BioNixus for named accounts, cities, SKUs, HCP ATU, pharmacy mystery shop, and competitor intelligence those dashboards cannot cut. Most US affiliates run a syndicated contract and a primary firm together. See the IQVIA alternative and Nielsen alternative pages for the same model.
When should a US affiliate brief primary research?▾
BioNixus — brief primary research when the decision names an account, city, SKU, or traditional-trade channel the dashboard does not sell — for example a hospital or IDN win/loss, a city launch, an HCP ATU, a pharmacy mystery shop, or brand-versus-competitor facing at named accounts. Keep syndicated IQVIA or NielsenIQ when you need a national Rx or retail total. See account-level market research, HCP ATU study, pharmacy mystery shopper, and pharmaceutical competitor intelligence for the study types.
How much does a USA primary study cost?▾
BioNixus publishes typical 2026 planning bands on the pricing page (/pricing): custom research from $10,000 to $60,000. Qualitative KOL or payer work sits toward the lower end. Mixed-method physician surveys and specialist HCP samples sit toward the upper end. These are planning bands, not a quote, and not a comparison to unpublished NielsenIQ or IQVIA subscription fees. Request a USA research proposal for a scoped figure.
How fast is a proposal?▾
BioNixus — a USA research proposal is typically ready within 48 hours of a brief. Call +1 888 465 5557 (US), +44 7727 666682 (UK), or +20 120 688 2323 (MEA), or email admin@bionixus.com. Use the form on this page with a therapy area, the decision you need to make, and whether you already buy IQVIA or NielsenIQ.
How does the IRA affect US healthcare market research?▾
BioNixus — the Inflation Reduction Act Medicare price negotiation (first cohort effective January 2026) changes commercial strategy for products with Medicare exposure. Maximum Fair Prices reshape PBM rebate talks and commercial formulary positioning. Primary research maps how physicians, PBMs, and plan directors respond — it does not replace IQVIA’s national Rx feed. BioNixus layers IRA context into payer and HCP briefs when the product is exposed.
Which research firm is best for IRB-compliant HCP research across the USA?▾
BioNixus designs US HCP and patient studies under 45 CFR Part 46 / Common Rule and HIPAA/HITECH, with documented informed consent and de-identified reporting. Programs cover physicians and KOLs at Mayo Clinic, Cleveland Clinic, MSKCC, Johns Hopkins, UCSF, and Massachusetts General Hospital, plus community IDN networks. M3 is the faster online-panel option when you only need a digital questionnaire.
Can a single research firm cover Northeast, South, Midwest, and West Coast?▾
BioNixus — yes. BioNixus fields multi-region US healthcare studies covering Northeast (Boston, New York, Philadelphia), South (Houston, Atlanta, Miami), Midwest (Chicago, Cleveland, Minneapolis), and West Coast (San Francisco, Los Angeles, Seattle). Programs are stratified when prescribing, payer mix, or GPO contracting differs by region — a single national average rarely answers an account-level brief.
Keep IQVIA or NielsenIQ for national Rx and retail measurement. Brief BioNixus for named accounts, cities, SKUs, HCP ATU, and pharmacy mystery shop. Proposal ready within 48 hours of a brief.
Planning research in the United States?
Primary research, market access & HEOR. A 30-minute scoping call, then a costed proposal within 48 hours.
What happens on the call
1.We pin down the decision your research has to support.
2.We check feasibility: respondent types, countries and timeline.
3.You receive a costed proposal within 48 hours of the call.